Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) – MS Wkly

Since Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of both companies.

Valuation and Earnings

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Liquidity

The Current Ratio and Quick Ratio of Osmotica Pharmaceuticals plc are 1.7 and 1.4 respectively. Its competitor VistaGen Therapeutics Inc.s Current Ratio is 4.9 and its Quick Ratio is 4.9. VistaGen Therapeutics Inc. can pay off short and long-term obligations better than Osmotica Pharmaceuticals plc.

Institutional & Insider Ownership

Osmotica Pharmaceuticals plc and VistaGen Therapeutics Inc. has shares owned by institutional investors as follows: 50.4% and 20.4%. 4% are Osmotica Pharmaceuticals plcs share owned by insiders. Comparatively, VistaGen Therapeutics Inc. has 0.2% of its share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Osmotica Pharmaceuticals plc was less bearish than VistaGen Therapeutics Inc.

Summary

On 5 of the 9 factors VistaGen Therapeutics Inc. beats Osmotica Pharmaceuticals plc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly